You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心通醫療-B(02160.HK)盈喜:預期2023年收入同比增長約31%至36%
格隆匯 02-28 22:56

格隆匯2月28日丨心通醫療-B(02160.HK)公吿,根據對集團截至2023年12月31日止年度未經審核綜合管理賬目及現時可得數據作出的初步評估,集團預期報吿期收入將在人民幣330百萬元至340百萬元,較截至2022年12月31日止年度收入人民幣251百萬元增長約為31%至36%。該等收入增長主要歸因於:

(i)公司的經導管主動脈瓣植入術("TAVI")產品在中華人民共和國入院的持續進展推動植入量和收入快速增加。於報吿期內,公司的TAVI產品新增進入中國117家醫院,較截至2022年12月31日的入院數量增加約27%。公司於報吿期內在中國的植入量較2022年增長約45%;及

(ii)公司的TAVI產品在海外的市場拓展及收入增加。截至2023年12月31日,公司的TAVI產品已進入阿根廷、哥倫比亞、泰國和俄羅斯的近百家醫院。於報吿期內,公司的TAVI產品共完成了120例海外商業植入,較2022年增長約90%。

此外,集團亦着力整合優勢資源,加速推進重點自主研發項目:公司的第三代TAVI產品Vita Flow®III已向國家藥品監督管理局("國家藥監局")遞交註冊申請;公司的經導管二尖瓣置換產品已完成10例人道主義應用,並持續推進臨牀隨訪,為產品後續開展大規模臨牀試驗積累臨牀經驗,同時已啟動型式檢驗;公司的左心耳封堵器產品Anchor Man®已獲得國家藥監局頒發的註冊批准和地方藥品監督管理部門頒發的生產許可證。

於報吿期內,集團積極執行資源聚焦和成本管控措施,持續降低生產成本,提升運營效率。未來,公司將以財務報表的健康度為重,通過聚焦業務、提高收入、節約成本、降低費用等措施,進一步減少虧損,致力於在保持收入穩步增長的前提下儘快實現盈虧平衡。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account